



Best Practices for Managing Infants with Apnea & Bradycardia of Prematurity

Clinical guidelines for management
and discharge planning

Definition

Apnea of prematurity (AOP) is commonly experienced by premature infants with an incidence inversely correlated with gestational age at birth. Nearly all babies less than 28 weeks of gestational age (GA) have this diagnosis, with 85% of those born at 30 weeks and 20% of those born at 34 weeks also experiencing AOP (Eichenwald 2016).

Nearly all babies less than 28 weeks of gestational age (GA) have this diagnosis

Studies have shown that events may persist in many babies, at least until the completion of 43-44 weeks post-menstrual age (PMA). These events can persist despite an “apnea-free” period of observation while in the hospital prior to discharge.

An apneic spell is usually defined as a cessation of breathing for 20 seconds or longer or a shorter pause accompanied by bradycardia (<100 beats per minute), cyanosis, or pallor. A clinically significant bradycardia is a heart rate less than 80 bpm for 5 seconds or more. (Patrinos 2020, Ahlfeld 2020, Eichenwald 2016, Guidelines for Perinatal Care 2017, Eichenwald 2017).

Underlying conditions, such as sepsis or anemia, that may cause apnea should be considered and excluded prior to making the diagnosis of AOP. Infants born less than 35 weeks of gestation should be observed for clinically significant apnea and managed accordingly. In addition to chest wall impedance, heart rate and pulse oximeter monitoring should be performed on infants at risk for AOP.

Apnea of Infancy refers to infants greater than 37 weeks gestational age at the onset of apnea. These events typically are associated with other etiologies (Benitz 2015).

Management

Prolonged or frequent events (defined as apnea >20 seconds and/or bradycardia with a heart rate 80 for at least 5 seconds) warrant evaluation to exclude underlying conditions and, if none are identified, treatment for AOP may be initiated (AbdelHady 2015).

Pharmacologic measures such as methylxanthine therapy, particularly caffeine citrate, are often added to the treatment regimen if significant events persist. After the loading (20 mg/kg) and maintenance doses (5-10 mg/kg/day) of caffeine are ordered, additional boluses and maintenance dose adjustments may be required if apnea persists (Sarooha 2020, Eichenwald 2016, AbdelHady 2015). Caffeine is the preferred prophylactic agent to prevent apnea of prematurity because of its longer half-life, wider margin of safety, and lower frequency of adverse effects when compared to theophylline (Schmidt 2023, Henderson- Smart 2010). Very low birth weight infants should be considered for caffeine therapy soon after birth if they:

1. Are extremely immature and receive positive airway pressure without an endotracheal tube
2. Are weaning from mechanical ventilation toward a trial of extubation
3. Have documented apnea (Schmidt 2023)

In addition to the benefit of acutely treating apnea of prematurity, long-term randomized-controlled Caffeine for Apnea of Prematurity (CAP) Trials have shown lower incidence of bronchopulmonary dysplasia (BPD), defined as oxygen treatment at 36 weeks postmenstrual age. In addition to possibly reducing incidences of clinically significant Patent ductus arteriosus (PDA), there is long-term neuro-developmental safety and potential efficacy for reduced motor and visual impairments as late as 11 years of age (Oliphant 2024, Schmidt 2023, Lodha 2019, Mürner-Lavanchy 2018, Schmidt 2017, Schmidt 2012, Schmidt 2007).



With proven benefits for caffeine therapy, there was a study that tried to determine if prolonged caffeine therapy was beneficial. The MOCHA trial (Moderately Preterm Infants with Caffeine at Home for Apnea) was a large randomized clinical trial for infants born at 29 to 33 weeks' gestation to evaluate whether extending caffeine treatment reduces the duration of hospitalization. The MOCHA trial was stopped early after an interim analysis met its prespecified futility criteria that showed continuation of caffeine treatment compared with placebo did not shorten hospitalization in moderately preterm infants (Carlo 2025)

Non-pharmacologic measures, besides stimulation (Martin 2020, Cramer 2018), may include the application of air flow via nasal cannula and/or the addition of supplemental oxygen if hypoxemia exists. These measures may be useful in infants corrected to greater than 34 weeks GA, so discharge is not delayed awaiting caffeine clearance. Thermoregulation, infant positioning, and airway patency should be optimized.

Higher positive pressures (i.e. Nasal Continuous Positive Airway Pressure (NCPAP), High-flow nasal cannula (HFNC), Nasal Intermittent Positive Pressure Ventilation (NIPPV), or mechanical ventilation) may be indicated if events are severe and persistent and are not responding to other interventions (Firestone 2020). Noninvasive support, including NCPAP, is preferred to minimize lung injury and reduce the risk of bronchopulmonary dysplasia, but there is acknowledgement that some infants—particularly those born at less than 25 weeks' gestation—may still require intubation and mechanical ventilation (Manley 2024). Red blood cell transfusions are sometimes prescribed in the presence of significant anemia with persistent and/or severe apnea, despite therapeutic caffeine levels (Lorch 2011).

A trial of discontinuation of caffeine should be considered at 33 weeks corrected gestational age (CGA) or after a five-day period with minimal or no events (off positive pressure), whichever comes first (Eichenwald 2016). If there are no continued events and no continued respiratory support needed, there is little to no difference in the incidence of mortality and apnea waiting until a later CGA (more than 35 weeks CGA) to stop caffeine (Urru 2024). Routine monitoring of caffeine levels is not necessary since monitoring for clinical symptoms has been shown to be more effective (Eichenwald 2016).

Procedure or care related events, or events that occur during feeding, must be distinguished from AOP and managed accordingly. Gastroesophageal reflux or suck/swallow incoordination are common conditions experienced by premature infants and are not associated with, nor contribute to, apnea of prematurity (Slocum 2009). Anti-reflux medications (i.e., antacids, prokinetic agents, proton-pump inhibitors) are not recommended in the neonate due to ineffectiveness and potential treatment complications of affecting the gastrointestinal tract adversely (Eichenwald 2016, Ho 2015, Tipnis 2009, Smith 2016).

An event-free period of up to 5 days for a preterm infant is a reasonable timeframe to demonstrate cardio-respiratory stability before safely discharging to home (Coughlin 2020). The specific event-free period may need to be individualized for some infants depending on the gestational age at birth and the nature and severity of recorded events (Eichenwald 2016). Lorch et al., recognized that a longer countdown period (i.e., 7 days) may be appropriate for infants born at 26 weeks or less (Lorch 2011).

An event-free period of up to 5 days for a preterm infant is a reasonable time frame to demonstrate cardio-respiratory stability

Due to the long half-life of caffeine, the infant should continue to be monitored for five days after caffeine treatment has been discontinued (Chavez 2022, Dabin 2020, Darnall 1997) and for those born at 26 weeks gestational age or less, 7 days may be warranted.

Episodes of bradycardia that are brief and isolated or associated with oral feeding are common in preterm infants and are generally not considered significant (Patrinos 2020, Ahlfeld 2020, Tieder 2016).

A 5-day watch is not needed with feeding related events. Many experts do not count feeding-relating episodes in determining when to discharge these infant due to these types of events having a different pathophysiology than a true apnea/bradycardia event (Eichenwald 2016, Coughlin 2020, Slocum 2009). Oral feeding-related events should not preclude discharge (Coughlin 2020). Depending on the severity of the feeding-related event and the intensity of any possible intervention needed, consider a shorter observation period than 5 days.

Discharge Planning

The discharge of infants with a history of apnea can be challenging for the clinician, given the lack of clinical consensus. There may be variations in properly defining a true apnea, bradycardia or desaturation event (Chandrasekharan 2020, Butler 2014, The Joint Commission Journal on Quality and Patient Safety 2016). There is also wide variation in the timing of caffeine discontinuation, despite recommendations from the Committee on Fetus and Newborn (2016), as mentioned above. Because caffeine has a long half-life, and to avoid unnecessary delays, it needs to be discontinued before the infant is ready to be discharged.

Monitoring for clinical symptoms is more important than testing caffeine levels. It has been shown that monitoring of routine caffeine levels was not contributory to management (Eichenwald 2016), and it should not affect discharge. Research shows that caffeine has a half-life range of 62 to 112 hours in neonates (Doyle 2016). A 5-day observation time period is reasonable to demonstrate cardiorespiratory stability before a safe discharge from the hospital.

Pneumocardiograms (PCGs) are not recommended in identifying which neonates should be discharged with a home monitor. PCGs have a high false positive rate and cannot accurately predict the occurrence of severe apnea or death (American Academy of Pediatrics Committee on Fetus and Newborn 2008). Since PCGs are not appropriate for routine screening, they are not an acceptable reason to delay discharge from the hospital (Ho 2015).

Infants who have been observed for an extended apnea-free or event-free period of time should be discharged without a monitor (Lorch 2011). The event-free period of time may vary based on the infant's gestational age at birth and characteristics of the recorded events (Eichenwald 2016).

Home cardio-respiratory monitors may be used to facilitate the discharge of stable premature infants who manifest occasional mild or self-resolved "events," without cyanosis or respiratory distress. Infants requiring ongoing caffeine therapy may be considered for discharge with a monitor.

Home apnea monitors would also be appropriate for neonates who have respiratory technology-dependency (low-flow nasal cannula, ventilator, tracheostomy with collar, gastrostomy, etc.), unstable airways, rare medical conditions affecting regulation of breathing, or symptomatic chronic lung disease issues (Farrell 2002, Ramanathan 2001, Silvestri 2005, Zupanic 2003).

The American Academy of Pediatrics recommends against the use of commercial or store-bought high-tech baby monitors (Moon 2022). Parents should understand that the use of a home monitor has not been demonstrated to reduce the rate of SIDS, even in premature infants (Finer 2006, Ramanathan 2001, Moon 2022). The rationale is that reliance on home monitoring may provide false reassurance, potentially leading to decreased adherence to safe sleep practices, and there is no evidence that such monitoring improves outcomes in this population (Goodstein 2021).

CPR training for parents and caregivers is highly recommended prior to discharge. Hospitals should ensure that training occurs in the facility, or that adequate instructional materials are provided, before discharging the infant.

References

1. Abdel-Hady H et al. Caffeine therapy in preterm infants. *World J Clin Pediatr*. 2015; 4(4): 81–93.
2. Ahlfeld SK. Respiratory tract disorders. In: Kliegman RM, St. Geme JW, Blum NJ, Shah SS, Tasker RC, Wilson KM, editors. *Nelson Textbook of Pediatrics*. 21st ed. Philadelphia, PA: Elsevier; 2020:929-949.e1.
3. American Academy of Pediatrics Committee on Fetus and Newborn. Hospital discharge of the high-risk neonate. *Pediatrics*. 2008; 122:1119-1126.
4. Benitz WE; Committee on Fetus and Newborn, American Academy of Pediatrics. Hospital stay for healthy newborn infants. *Pediatrics*. 2015 May;135(5):948-953.
5. Butler et al. Standardizing documentation and the clinical approach to apnea of prematurity reduces length of stay, improves staff satisfaction, and decreases hospital cost. *Jt Comm J Qual Patient Saf* 2014. 40(6):263-9.
6. Carlo WA, Eichenwald EC, Carper BA, et al. Extended Caffeine for Apnea in Moderately Preterm Infants: The MoCHA Randomized Clinical Trial. *JAMA*. 2025;333(24):2154–2163. doi:10.1001/jama.2025.5791
7. Chandrasekharan et al. Apnea, bradycardia and desaturation spells in premature infants: impact of a protocol for the duration of ‘spell-free’ observation on interprovider variability and readmission rates. *J Perinatol* 2018. 38(1):86-91.
8. Chavez L, Bancalari E. Caffeine: some of the evidence behind its use and abuse in the preterm infant. *Neonatology*. 2022;119(4):428–32.
9. Coughlin K et al. Reducing Variation in the Management of Apnea of Prematurity in the Intensive Care Nursery. *Pediatrics* February 2020, 145 (2) e20190861
10. Cramer et al. Effect of Tactile Stimulation on Termination and Prevention of Apnea of Prematurity: A Systematic Review. *Front Pediatr* 2018. 6:45.
11. Dabin J et al.; Wide variation in caffeine discontinuation timing in premature infants. *J Perinatol*. 2020; 40(2): 288–293.
12. Darnall R et al. Margin of safety for discharge after apnea in preterm infants. *Pediatrics* 1997; 100:795-801.
13. Doyle J, et al. Apnea of prematurity and caffeine pharmacokinetics: potential impact on hospital discharge. *J Perinatol*. 2016;36(2):141–144.
14. Eichenwald EC and AAP Committee on Fetus and Newborn, AAP Clinical Report: Apnea of Prematurity. *Pediatrics* 2016; 137. DOI: 10.1542/peds.2015-3757.
15. Eichenwald EC, et al, editors, Cloherty and Stark’s Manual of Neonatal Care, Eighth Edition, 2017.
16. Farrell PA et al. SIDS, ALTE, apnea and the use of home monitors. *Pediatrics in Review* 2002; 23:3-9.
17. Finer NN et al. Summary proceedings from the apnea of prematurity group. *Pediatrics* 2006;117: S47-S51.
18. Firestone K, Horany BA, de Leon-Belden L, Stein H. Nasal continuous positive airway pressure versus noninvasive NAVA in preterm neonates with apnea of prematurity: a pilot study with a novel approach. *J Perinatol* 2020; 40:1211.
19. Guidelines for Perinatal Care, Eighth Edition, 2017 AAP and ACOG, pp 410-411, 464-468.
20. Goodstein MH, Stewart DL, Keels EL, Moon RY. Transition to a Safe Home Sleep Environment for the NICU Patient. *Pediatrics*. 2021;148(1):e2021052046. doi:10.1542/peds.2021-052046.
21. Henderson-Smart DJ, Steer PA; Caffeine versus theophylline for apnea in preterm infants. *Cochrane Database Syst Rev*. 2010.
22. Ho T, Dukhovny D, Zupancic JA, et al. Choosing wisely in newborn medicine: Five opportunities to increase value. *Pediatrics*. 2015 Aug;136(2): e482-9.
23. Lodha A, et al. Early Caffeine Administration and Neurodevelopmental Outcomes in Preterm Infants. *Pediatrics* 2019; 143(1)
24. Lorch S et al, Epidemiology of Apnea and Bradycardia Resolution in Premature Infants. *Pediatrics* 2011;128; e366.

25. Manley BJ, Cripps E, Dargaville PA. Non-invasive versus invasive respiratory support in preterm infants. *Semin Perinatol*. 2024 Mar;48(2):151885. doi: 10.1016/j.semperi.2024.151885. Epub 2024 Mar 23. PMID: 38570268.
26. Martin et al. Light or Deep Pressure: Medical Staff Members Differ Extensively in Their Tactile Stimulation During Preterm Apnea. *Frontiers in Pediatrics* 2020. 8:102.
27. Moon RY, Carlin RF, Hand I; Task Force on Sudden Infant Death Syndrome and the Committee on Fetus and Newborn. Sleep-related infant deaths: updated 2022 recommendations for reducing infant deaths in the sleep environment. *Pediatrics*. 2022;150(1):e2022057990.
28. Mürner-Lavanchy IM, et al.; Neurobehavioral Outcomes 11 Years After Neonatal Caffeine Therapy for Apnea of Prematurity. *Pediatrics*. 2018;141(5) Epub 2018 Apr 11.
29. Oliphant EA, Hanning SM, McKinlay CJD, Alsweiler JM. Caffeine for apnea and prevention of neurodevelopmental impairment in preterm infants: systematic review and meta-analysis. *J Perinatol* 2024; 44:785.
30. Patrinis ME. Neonatal apnea and the Foundation of Respiratory Control. In: Martin RJ, Fanaroff AA, editors. *Fanaroff and Martin's Neonatal-Perinatal Medicine*. 11th ed. Philadelphia, PA: Elsevier; 2020:1231-1243
31. Ramanathan R et al. Cardiorespiratory events recorded on home monitors-comparison of healthy infants with those at increased risk of SIDS. *JAMA* 2001; 285:2199-2207.
32. Saroha V, Patel RM. Caffeine for preterm infants: fixed standard dose, adjustments for age or high dose. *Semin Fetal Neonatal Med*. 2020 Dec;25(6):10117829.
33. Schmidt B et al. Long-term effects of caffeine therapy for apnea of prematurity. *N Engl J Med* 2007; 357:1893-1902
34. Schmidt B, Davis PG, Roberts RS. Timing of caffeine therapy in very low birth weight infants. *J Pediatr* 2014; 164:957-8.
35. Schmidt B, et al.; Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial. *JAMA Pediatr*. 2017;171(6):564-772.
36. Schmidt B, et al.; Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. *JAMA*. 2012 Jan;307(3):275-82.
37. Schmidt B. Caffeine for Apnea of Prematurity: Too Much or Too Little of a Good Thing, *The Journal of Pediatrics* 2023, Volume 259, 113488
38. Silvestri JM et al. Factors that influence use of a home cardiorespiratory monitor for infants (CHIME). *Archives of Pediatrics and Adolescent Medicine*. 2005; 159:18-24.
39. Slocum C et al. Apnea, bradycardia, and desaturation in preterm infants before and after feeding. *J Perinatol*. 2009 March; 29(3): 209–212. doi:10.1038/jp.2008.226
40. Smith PB, Use of Reflux Medications in Premature Infants After Hospital Discharge *Pediatrics* December 2016, 138 (6)
41. The Joint Commission Journal on Quality and Patient Safety: Evidence-Based Medicine Standardizing Documentation and the Clinical Approach to Apnea of Prematurity Reduces Length of Stay, Improves Staff Satisfaction, and Decreased Hospital Cost. June 2016, Volume 40:6, 263-269
42. Tipnis NA, Tipnis SM. Controversies in the treatment of gastroesophageal reflux disease in preterm infants. *Clinics in Perinatology*. 2009;36(1):153-164.
43. Tieder JS, Bonkowsky JL, Etzel RA, et al. Brief Resolved Unexplained Events (Formerly Apparent Life-Threatening Events) and Evaluation of Lower-Risk Infants. *Pediatrics*. 2016 May. 137 (5)
44. Urru SA, Geist M, Carlinger R, et al. Strategies for cessation of caffeine administration in preterm infants. *Cochrane Database Syst Rev* 2024; 7:CD015802.
45. Zupanec JAF et al. Cost-effectiveness analysis of predischarge monitoring for apnea of prematurity. *Pediatrics* 2003; 111:146-152



About ProgenyHealth

ProgenyHealth's 130+ full-time, NICU-specialized physicians and nurses have managed hundreds of thousands of cases to-date, working collaboratively supporting their colleagues on the front lines of hospitals across the country. The benefit to our plan partners is consistent and accurate authorizations which ensure that each and every infant receives the right level of care in the right setting, based on their unique clinical circumstances and health care needs.

**For more information or to sign up for future blogs,
visit www.progenyhealth.com.**